According to this article in the Chicago Tribune, Abbott Laboratory's new drug-coated stent, Xience, which goes on sale in Europe next month, did better in a trial than the current market leader, Boston Scientific Corp's Taxus.
Stents are wire mesh devices that are used to unblock clogged arteries. Stents are now being drug-coated, because uncoated stents sometimes close in patients.
0 comments:
Post a Comment